Abiopharma

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

InspireMD Reports Third Quarter 2025 Financial Results

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

Zoetis Announces Third Quarter 2025 Results

EDAP to Present at Jefferies Global Healthcare Conference in London

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Compugen to Participate in Stifel 2025 Healthcare Conference